 BEIJING, Sept. 24, 2019 PRNewswire -- China Biologic Products Holdings, Inc. NASDAQ: CBPO, China Biologic or the Company, a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its board of directors the Board has formed a special committee the Special Committee to review and evaluate the previously announced preliminary non-binding going private proposal the Proposal that the Board received on September 18, 2019 from Beachhead Holdings Limited, CITIC Capital China Partners IV, L.P., PW Medtech Group Limited, Parfield International Ltd., HH Sum-XXII Holdings Limited and V-Sciences Investments Pte. Ltd. The Special Committee is composed of Mr. Sean Shao, Dr. Yungang Lu and Mr. Qi Ning, who are independent directors of the Company and are unaffiliated with the Proposal. 